Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


eCase: Treatment of Tardive Dyskinesia Using Valbenazine in a Patient With Schizophrenia
  • CME
  • CE

This eCase explores diagnosis and treatment of tardive dyskinesia in a male patient with schizophrenia.
John M. Kane, MD
Physicians: maximum of 0.75 AMA PRA Category 1 Credits
Registered Nurses: 0.75 Nursing contact hours
Pharmacists: 0.75 contact hours (0.075 CEUs)
Physician Assistants: maximum of 0.75 hours of AAPA Category 1 CME credits
Released: November 3, 2021 Expiration: November 2, 2022

CCO's Interactive Case Challenges guide you through a clinical scenario where the case unfolds according to your choices. If you make a management decision that the faculty member considers to be suboptimal, you'll see the consequences of that choice and be able to mitigate it, before revisiting the questionable decision. Each case ends with a recap of the key learning points and a summary of studies and guidelines that underpin the faculty recommendations.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Discuss tardive dyskinesia symptoms and screening approaches
  • Formulate evidence-based treatment for TD


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant provided by
Neurocrine Biosciences, Inc.

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:


John M. Kane, MD

Vice President for Behavioral Health Services
Northwell Health
Chairman of Psychiatry
Zucker Hillside Hospital
Queens, New York
Chairman of Psychiatry
Professor of Psychiatry and Molecular Medicine
Zucker School of Medicine at Hofstra/Northwell
Hempstead, New York

John M. Kane, MD, has disclosed that he has received funds for research support from H. Lundbeck, Janssen, and Otsuka; has received consulting fees from Alkermes, Allergan, Dainippon Sumitomo, H. Lundbeck, Intra-Cellular Therapies, Janssen, LB Pharmaceuticals, Lyndra, Merck, Neurocrine Biosciences, Otsuka, Reviva, Roche, Saladex, Sunovion, Takeda, and Teva; has ownership interest in LB Pharmaceuticals, Merck, Minerva, and North Shore Therapeutics; and has received fees for non-CME/CE services from Dainippon Sumitomo, H. Lundbeck, Janssen, and Otsuka.


Aditi Nadkarni, PhD
Aditi Nadkarni, PhD, has no relevant conflicts of interest to report.
Lisa Phipps, PharmD, PhD
Lisa Phipps, PharmD, PhD, has no relevant conflicts of interest to report.
Julie Skowronski, FNP-BC
Julie Skowronski, NP, has no relevant conflicts of interest to report.
Mark Christiansen, PhD, PA-C
Mark Christiansen, PA, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for physicians, advanced practice providers, pharmacists and pharmacy technicians, nurses, and physician assistants engaged in the care of patients with psychiatric illness.


The goal of this activity is to use a patient case study to improve learner competency in evaluating diagnostic considerations and treatment options for tardive dyskinesia.


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

Continuing Pharmacy Education

Credit Designation

CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-21-230-H01-P.

Type of Activity: Knowledge

Upon successfully completing the post-test with a score of 50% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Assistant Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until November 2, 2022. PAs should only claim commensurate with the extent of their participation.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.75 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from November 03, 2021, through November 02, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Slides from a presentation that educates clinicians on the identification and management of tardive dyskinesia.

Christoph U. Correll, MD Robert O. Cotes, MD Released: May 11, 2022

Slides from a presentation that educates clinicians on antipsychotic treatment of schizophrenia.

Christoph U. Correll, MD Robert O. Cotes, MD Released: May 11, 2022

Slides from a presentation that educates clinicians on managing major depression.

Manish Jha, MD Greg W. Mattingly, MD Released: May 11, 2022

Slides from a presentation that educates clinicians on managing bipolar depression and mixed presentations

Charles DeBattista, MD Roger McIntyre, MD, FRCPC Released: May 9, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings